AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within...

Descripción completa

Detalles Bibliográficos
Autores principales: Ivashchenko, Andrey A, Dmitriev, Kirill A, Vostokova, Natalia V, Azarova, Valeria N, Blinow, Andrew A, Egorova, Alina N, Gordeev, Ivan G, Ilin, Alexey P, Karapetian, Ruben N, Kravchenko, Dmitry V, Lomakin, Nikita V, Merkulova, Elena A, Papazova, Natalia A, Pavlikova, Elena P, Savchuk, Nikolay P, Simakina, Elena N, Sitdekov, Tagir A, Smolyarchuk, Elena A, Tikhomolova, Elena G, Yakubova, Elena V, Ivachtchenko, Alexandre V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454388/
https://www.ncbi.nlm.nih.gov/pubmed/32770240
http://dx.doi.org/10.1093/cid/ciaa1176
_version_ 1783575494362398720
author Ivashchenko, Andrey A
Dmitriev, Kirill A
Vostokova, Natalia V
Azarova, Valeria N
Blinow, Andrew A
Egorova, Alina N
Gordeev, Ivan G
Ilin, Alexey P
Karapetian, Ruben N
Kravchenko, Dmitry V
Lomakin, Nikita V
Merkulova, Elena A
Papazova, Natalia A
Pavlikova, Elena P
Savchuk, Nikolay P
Simakina, Elena N
Sitdekov, Tagir A
Smolyarchuk, Elena A
Tikhomolova, Elena G
Yakubova, Elena V
Ivachtchenko, Alexandre V
author_facet Ivashchenko, Andrey A
Dmitriev, Kirill A
Vostokova, Natalia V
Azarova, Valeria N
Blinow, Andrew A
Egorova, Alina N
Gordeev, Ivan G
Ilin, Alexey P
Karapetian, Ruben N
Kravchenko, Dmitry V
Lomakin, Nikita V
Merkulova, Elena A
Papazova, Natalia A
Pavlikova, Elena P
Savchuk, Nikolay P
Simakina, Elena N
Sitdekov, Tagir A
Smolyarchuk, Elena A
Tikhomolova, Elena G
Yakubova, Elena V
Ivachtchenko, Alexandre V
author_sort Ivashchenko, Andrey A
collection PubMed
description In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. Clinical Trials Registration. NCT04434248.
format Online
Article
Text
id pubmed-7454388
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-74543882020-08-31 AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial Ivashchenko, Andrey A Dmitriev, Kirill A Vostokova, Natalia V Azarova, Valeria N Blinow, Andrew A Egorova, Alina N Gordeev, Ivan G Ilin, Alexey P Karapetian, Ruben N Kravchenko, Dmitry V Lomakin, Nikita V Merkulova, Elena A Papazova, Natalia A Pavlikova, Elena P Savchuk, Nikolay P Simakina, Elena N Sitdekov, Tagir A Smolyarchuk, Elena A Tikhomolova, Elena G Yakubova, Elena V Ivachtchenko, Alexandre V Clin Infect Dis Brief Reports In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. Clinical Trials Registration. NCT04434248. Oxford University Press 2020-08-09 /pmc/articles/PMC7454388/ /pubmed/32770240 http://dx.doi.org/10.1093/cid/ciaa1176 Text en © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Reports
Ivashchenko, Andrey A
Dmitriev, Kirill A
Vostokova, Natalia V
Azarova, Valeria N
Blinow, Andrew A
Egorova, Alina N
Gordeev, Ivan G
Ilin, Alexey P
Karapetian, Ruben N
Kravchenko, Dmitry V
Lomakin, Nikita V
Merkulova, Elena A
Papazova, Natalia A
Pavlikova, Elena P
Savchuk, Nikolay P
Simakina, Elena N
Sitdekov, Tagir A
Smolyarchuk, Elena A
Tikhomolova, Elena G
Yakubova, Elena V
Ivachtchenko, Alexandre V
AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
title AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
title_full AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
title_fullStr AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
title_full_unstemmed AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
title_short AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
title_sort avifavir for treatment of patients with moderate coronavirus disease 2019 (covid-19): interim results of a phase ii/iii multicenter randomized clinical trial
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454388/
https://www.ncbi.nlm.nih.gov/pubmed/32770240
http://dx.doi.org/10.1093/cid/ciaa1176
work_keys_str_mv AT ivashchenkoandreya avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial
AT dmitrievkirilla avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial
AT vostokovanataliav avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial
AT azarovavalerian avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial
AT blinowandrewa avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial
AT egorovaalinan avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial
AT gordeevivang avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial
AT ilinalexeyp avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial
AT karapetianrubenn avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial
AT kravchenkodmitryv avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial
AT lomakinnikitav avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial
AT merkulovaelenaa avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial
AT papazovanataliaa avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial
AT pavlikovaelenap avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial
AT savchuknikolayp avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial
AT simakinaelenan avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial
AT sitdekovtagira avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial
AT smolyarchukelenaa avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial
AT tikhomolovaelenag avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial
AT yakubovaelenav avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial
AT ivachtchenkoalexandrev avifavirfortreatmentofpatientswithmoderatecoronavirusdisease2019covid19interimresultsofaphaseiiiiimulticenterrandomizedclinicaltrial

Ejemplares similares